Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Opium (Opioid) Addiction Treatment Pipeline Review H2 2016

Sunday, October 30, 2016 23:47
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Opium (Opioid) Addiction – Pipeline Review, H2 2016’, provides an overview of the Opium (Opioid) Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real-time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ https://www.wiseguyreports.com/sample-request/711812-opium-opioid-addiction-pipeline-review-h2-2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction
- The report reviews pipeline therapeutics for Opium (Opioid) Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Opium (Opioid) Addiction therapeutics and enlists all their major and minor projects
- The report assesses Opium (Opioid) Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Complete report details @ https://www.wiseguyreports.com/reports/711812-opium-opioid-addiction-pipeline-review-h2-2016

 

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Report Coverage 8
Opium (Opioid) Addiction Overview 9
Therapeutics Development 10
Pipeline Products for Opium (Opioid) Addiction – Overview 10
Pipeline Products for Opium (Opioid) Addiction – Comparative Analysis 11
Opium (Opioid) Addiction – Therapeutics under Development by Companies 12
Opium (Opioid) Addiction – Therapeutics under Investigation by Universities/Institutes 14
Opium (Opioid) Addiction – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Opium (Opioid) Addiction – Products under Development by Companies 19
Opium (Opioid) Addiction – Products under Investigation by Universities/Institutes 20
Opium (Opioid) Addiction – Companies Involved in Therapeutics Development 21
Alkermes Plc 21
Aoxing Pharmaceutical Company, Inc 22
BioDelivery Sciences International, Inc. 23
Camurus AB 24
Foresee Pharmaceuticals, LLC 25
Heron Therapeutics, Inc. 26
Indivior Plc 27
INSYS Therapeutics, Inc. 28
Omeros Corporation 29
Pfizer Inc. 30
Relmada Therapeutics, Inc. 31
Teva Pharmaceutical Industries Ltd. 32
Titan Pharmaceuticals, Inc. 33
Zynerba Pharmaceuticals, Inc. 34
Opium (Opioid) Addiction – Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
(buprenorphine hydrochloride + naloxone hydrochloride) – Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
(buprenorphine hydrochloride + naloxone hydrochloride) – Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
(buprenorphine hydrochloride + naloxone hydrochloride) – Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
(buprenorphine hydrochloride + samidorphan l-malate) – Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
buprenorphine hydrochloride – Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
buprenorphine hydrochloride – Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
buprenorphine hydrochloride – Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
buprenorphine hydrochloride depot – Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
buprenorphine hydrochloride ER – Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
buprenorphine hydrochloride long acting – Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
buprenorphine hydrochloride SR – Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
cannabidiol – Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
cannabidiol – Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
FP-004 – Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
naltrexone hydrochloride – Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
naltrexone hydrochloride – Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
OMS-405 – Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
OMS-527 – Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
ORP-107 – Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
PF-5006739 – Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
samidorphan l-malate – Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
TA-CD – Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
TEV-90109 – Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Vaccine for Opium Addiction – Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Opium (Opioid) Addiction – Dormant Projects 83
Opium (Opioid) Addiction – Discontinued Products 84
Opium (Opioid) Addiction – Product Development Milestones 85
Featured News & Press Releases 85
Aug 16, 2016: Indivior Announces Positive Top-line Phase 3 Pivotal Study Results for RBP-6000 Buprenorphine Monthly Depot for the Treatment of Opioid Use Disorder 85
Aug 02, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Juan on August 5, 6 and 7 for Qualified Healthcare Providers 86
Jul 26, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Burlington on July 29 and 30 for Qualified Healthcare Providers 87
Jul 19, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings on July 22, 23 and 24 for Qualified Healthcare Providers in US 88
Jul 19, 2016: Buprenorphine implants may be effective relapse prevention tool for adults with opioid dependence 88
Jul 12, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Tampa on July 15, 16 and 17 for Qualified Healthcare Providers 89
Jun 29, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Antonio on July 8 and 9 for Qualified Healthcare Providers 90
Jun 21, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in St. Louis on June 24 and 25 for Qualified Healthcare Providers 90
Jun 20, 2016: Titan Pharmaceuticals Announces First Patients Treated With Probuphine For Opioid Dependence 91
Jun 16, 2016: Probuphine (buprenorphine) Implant Phase 3 Data Presented at CPDD Annual Scientific Meeting 92
Jun 15, 2016: Titan Pharmaceuticals Announces Rigorous Sensitivity Analyses Confirm Effectiveness of Probuphine for Opioid Dependence 92
Jun 14, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Francisco on June 17, 18 and 19 for Qualified Healthcare Providers 93
Jun 13, 2016: Titan Pharmaceuticals Receives $15 Million Milestone Payment Following FDA Approval of Probuphine 94
Jun 09, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Louisville on June 10, 11 and 12 for Qualified Healthcare Providers 95
Jun 07, 2016: MonoSol Rx Wins Patent Infringement Suit Against Par Pharmaceutical and Watson Pharmaceuticals Related to Suboxone Sublingual Film 96
Appendix 97
Methodology 97
Coverage 97
Secondary Research 97
Primary Research 97
Expert Panel Validation 97
Contact Us 97
Disclaimer 98

 

Get It now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=711812

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.